text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자\xa0현황\xa0\xa0기업집단의 명칭: 셀트리온(주)셀트리온은「독점규제 및\xa0공정거래에 관한 법률」상 셀트리온그룹에 속한 계열회사로서\xa02020년 2분기말 현재\xa0계열회사 현황은 아래와 같습니다. \n(기준일: 2020년 06월 30일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투\xa0 자\xa0 자\n서 정 진\n(주)셀트리온\n(주)셀트리온홀딩스\n(주)셀트리온헬스케어\n(주)셀트리온스킨큐어\n(주)셀트리온제약\n계\n(주)셀트리온\n133-81-23603\n-\n-\n20.03\n-\n2.12\n-\n22.15\n(주)셀트리온홀딩스\n131-86-24858\n95.51\n\xa0-\n-\n\xa0-\n\xa0-\n\xa0-\n95.51\n(주)셀트리온헬스케어\n123-81-53473\n35.62\n\xa0-\n\xa0-\n\xa0-\n1.39\n\xa0-\n37.01\n(주)셀트리온스킨큐어\n105-86-13560\n70.23\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n70.23\n(주)셀트리온제약\n214-86-71641\n\xa0-\n54.97\n-\n\xa0-\n\xa0-\n\xa0-\n54.97\n(주)셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n\xa0-\n\xa0-\n100.00\n㈜셀트리온 충북대 바이오메딕스\n417-87-01299\n-\n50.00\n-\n-\n-\n-\n50.00\n㈜셀트리온 충북대 코스메틱스\n338-88-01033\n-\n-\n-\n-\n50.00\n-\n50.00\n나. 회사와 계열회사간 임원 겸직 현황\n성명\n계열회사 겸직현황\n회사명\n직위\n상근여부\n서정진\n셀트리온홀딩스\n사내이사\n상근\n셀트리온제약\n사내이사\n상근\n셀트리온헬스케어\n사내이사\n상근\n셀트리온엔터테인먼트\n기타비상무이사\n비상근\n다. 타법인출자 현황\xa0\n(기준일 :\xa0\n2020년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc (비상장).\n2006.07.14\n신약개발투자\n2,676,548\n987,889\n16.51\n107,289\n0\n0\n9,059\n987,889\n16.51\n116,348\n1,971,082\n-314,586\n셀트리온 유럽 (비상장).\n2009.07.21\n유럽임상관련투자\n2\n1\n100\n2\n0\n0\n0\n1\n100\n2\n2\n0\n바이오톡스텍 (상장)\n2009.07.28\n투자수익\n2,025,000\n1,631,134\n11.18\n10,243,521\n0\n0\n5,317,497\n1,631,134\n11.18\n15,561,018\n60,584,722\n-1,410,890\n보스톤 인큐베이션투자조합 (비상장).\n2009.11.27\n투자수익\n2,500,000\n11\n25\n83,007\n0\n0\n0\n11\n25\n83,007\n338,536\n-257,982\n셀트리온 예브라지아 (비상장).\n2009.12.09\n사업다각화\n392\n1\n100\n393\n0\n0\n0\n1\n100\n393\n393\n0\n제이티비씨 (비상장).\n2017.09.20\n투자수익\n500,000\n100,000\n0.09\n44,896\n0\n0\n-15,440\n100,000\n0.09\n29,456\n293,083,720\n-24,879,636\n프리미어 글로벌이노베이션 1호 (비상장).\n2017.06.15\n유망 바이오벤처기업투자\n250,000\n3,482\n6.67\n3,333,335\n0\n0\n165,222\n3,482\n6.67\n3,498,557\n50,379,689\n109,906\n매일방송 (비상장).\n2011.03.17\n투자수익\n1,000,000\n250,981\n0.45\n1,475,167\n0\n0\n0\n250,981\n0.48\n1,475,167\n392,574,137\n5,632,910\n뉴스1 (비상장).\n2011.06.09\n투자수익\n500,000\n60,000\n5\n202,251\n0\n0\n0\n60,000\n5\n202,251\n18,409,363\n2,005,109\n셀트리온제약 (상장)\n2013.04.23\n경영참가 등\n50,057,259\n18,744,943\n54.99\n255,342,176\n937,247\n0\n0\n19,682,190\n54.97\n255,342,176\n470,980,396\n9,526,146\n2014 성장사다리-IMM벤처펀드 (비상장).\n2014.08.11\n투자수익\n2,000,000\n3,793\n20\n2,977,244\n-556\n-556,000\n0\n3,237\n20\n2,421,244\n16,643,722\n1,726,447\n미래에셋셀트리온신성장투자조합 1호 (비상장).\n2017.03.31\n유망 바이오벤처기업투자\n6,250,000\n438\n50\n43,750,000\n-50\n-5,000,000\n0\n388\n50\n38,750,000\n88,806,475\n2,138,294\nCelltrion Global Safety Data Center (비상장).\n2018.05.23\n글로벌 의약품안전성 데이터 관리\n1,106,930\n580,564\n99.99\n1,204,581\n0\n0\n0\n580,564\n99.99\n1,204,581\n1,903,425\n54,372\nCelltrion USA, Inc.(비상장).\n2018.07.24\n케미컬의약품판매유통망 구축\n38,973\n1,000\n100\n2,332,531\n250\n607,950\n0\n1,250\n100\n2,940,481\n13,330,947\n1,125\nCelltrion Group Hongkong ltd (비상장)\n2019.04.01\n바이오의약품중국사업\n5,680,500\n7,000,000\n70\n8,059,100\n23,270\n27,265\n0\n7,023,270\n70\n8,086,365\n22,089,849\n-2,599,074\n셀트리온충북대바이오메딕스 (비상장).\n2018.07.18\n신약 및 원료의약품연구개발\n100,000\n\xa0 \xa0 \xa0\xa0 20,000\n50\n100,000\n0\n0\n0\n20,000\n50\n100,000\n168,969\n-19,577\n합 계\n29,384,237\n0\n329,255,493\n960,161\n-4,920,785\n5,476,338\n30,344,398\n0\n329,811,046\n1,431,265,427\n-8,287,436\n*최근 사업연도 재무현황은 2019년도 말 기준으로 작성하였음\n']"
